Bonus Biogroup Ltd
TASE:BONS
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
9
28.1
|
| Price Target |
|
We'll email you a reminder when the closing price reaches ILS.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Bonus Biogroup Ltd
Cash Equivalents
Bonus Biogroup Ltd
Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
Bonus Biogroup Ltd
TASE:BONS
|
Cash Equivalents
₪14.1m
|
CAGR 3-Years
-44%
|
CAGR 5-Years
59%
|
CAGR 10-Years
40%
|
|
|
Collplant Biotechnologies Ltd
NASDAQ:CLGN
|
Cash Equivalents
$26.7m
|
CAGR 3-Years
100%
|
CAGR 5-Years
38%
|
CAGR 10-Years
N/A
|
|
|
Kamada Ltd
NASDAQ:KMDA
|
Cash Equivalents
$72m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
21%
|
CAGR 10-Years
15%
|
|
|
Enlivex Therapeutics Ltd
NASDAQ:ENLV
|
Cash Equivalents
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Urogen Pharma Ltd
NASDAQ:URGN
|
Cash Equivalents
$124.9m
|
CAGR 3-Years
31%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
|
|
Entera Bio Ltd
NASDAQ:ENTX
|
Cash Equivalents
$6.9m
|
CAGR 3-Years
-37%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
Bonus Biogroup Ltd
Glance View
Bonus Biogroup Ltd. is a biotechnology company engaging in the field of stem cells and tissue engineering. The firm is developing cell therapy products based on autologous and allogeneic bone implants that will enable efficient bone transplant and provide cellular-based bone replacement prosthetics for repairing bone lesions. The company is targeting a worldwide market for the treatment of major disorders such as bone and cartilage related arthritis, osteoporosis, and various types of bones and joint trauma such as hip fractures and knee injuries, among others. On April 29, 2012, Bonus Bio Group Ltd fully acquired Bonus Therapeutic Ltd.
See Also
What is Bonus Biogroup Ltd's Cash Equivalents?
Cash Equivalents
14.1m
ILS
Based on the financial report for Jun 30, 2024, Bonus Biogroup Ltd's Cash Equivalents amounts to 14.1m ILS.
What is Bonus Biogroup Ltd's Cash Equivalents growth rate?
Cash Equivalents CAGR 10Y
40%
Over the last year, the Cash Equivalents growth was -64%. The average annual Cash Equivalents growth rates for Bonus Biogroup Ltd have been -44% over the past three years , 59% over the past five years , and 40% over the past ten years .
You don't have any saved screeners yet
